Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

CTO in patients with acute myocardial infarction increases long term mortality

Courtesy of Dr. Carlos Fava.

CTO in Patients with Acute Myocardial Infarction Increases MortalityIt has been proved that in a setting of acute myocardial infarction with multivessel lesions, only the culprit vessel must be treated (if there is no hemodynamic compromise) at first, and other severe lesions are to be treated during a second session. However, proper conduct in cases with presence of chronic total occlusion (CTO) is still somewhat unclear.

 

As regards a total population of 836 patients who underwent primary angioplasty, 437 patients (52.3%: 31.3% with 2-vessel disease and 20.9% with 3-vessel disease) presented multivessel disease (MVD) and 146 (17.5%) presented CTO.

 

A comparative analysis was carried out between patients presenting MVD and those with CTO. The latter were more likely to have a history of diabetes, and had a more frequent history of acute myocardial infarction and angioplasty, but a less frequent history of prior myocardial infarction.

 

There was no difference as regards final thrombolysis in myocardial infarction (TIMI) flow 2 or 3.

 

Thirty-day mortality was 4.8% (CTO: 6.8% vs. MVD: 3.8%; p = 0.167); only age was a predictor of mortality (odds ratio [OR]: 1.07; 95% confidence interval [CI]: 1.01-11; p = 0.005).

 

One-year global mortality and cardiac mortality rates for MVD patients were 11% and 10%, respectively, higher than for patients with CTO in both cases (15.8% vs. 8.6%; p = 0.02, and 15% vs. 7.6%; p = 0.001).

 

After a 6-year follow-up, 129 patients (29.7%) in the MVD group had died, more than the number of deaths among patients with CTO (38.6% vs. 25.4%; p = 0.005).

 

CTO was a predictor of long-term mortality (OR: 2.07; 95% CI: 1.3-3.28; p = 0.002), as were age, prior acute myocardial infarction, and angioplasty failure.

 

Conclusion

The presence of CTO is an independent predictor of long-term mortality in ST-elevation myocardial infarction (STEMI) patients treated with primary angioplasty.

 

Editorial Comment

The presence of CTO in STEMI patients warns us about the posibility of more comorbidities and a highly negative impact on their progress.

 

As regards these patients, we need to be stricter in our search for residual ischemia and medical treatment has to be more aggressive. We must also attempt to treat CTO with angioplasty through different strategies, in order to improve survival.

 

More research on this subject is necessary. Randomized studies should be carried out in order to determine the minimum ischemic value necessary for revascularization.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Impact of the Presence of Chronically Occluded Coronary on Long-Term Prognosis of Patients with Acute ST-Segment Elevation Myocardial Infarction.

Reference: Maciej Lesiak et al. Cardiology J 2017;24,2:117-124.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

 

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...